• Analysis of 20 muscle-preservation programs highlights a rapidly emerging category designed to enhance long-term obesity treatment outcomes  • PatentVest&#39;s report reveals how combination therapy IP, body-composition

MDBH

New PatentVest Pulse Report Maps the Emerging Muscle-Preservation Category Expanding the GLP-1 Opportunity

MDBH Positioned to Benefit from Muscle-Preservation IP in Obesity Therapeutics

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>• Analysis of 20 muscle-preservation programs highlights a rapidly emerging category designed to enhance long-term obesity treatment outcomes  • PatentVest&amp;#39;s report reveals how combination therapy IP, body-composition</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>PatentVest released the Pulse report identifying 20 muscle-preservation programs and outlining how myostatin inhibition and GLP-1 combos could reshape obesity therapeutics. The findings highlight IP opportunities and strategic M&amp;A activity (Lilly&#039;s Versanis Bio/bimagrumab and AstraZeneca&#039;s SixPeaks) that could expand demand for PatentVest&#039;s IP intelligence services, benefiting MDBH.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>PatentVest identifies 20 muscle-preservation programs in development. Signals rising investor interest in obesity body composition.</li><li>Lilly&#039;s Versanis Bio and bimagrumab deals and AstraZeneca&#039;s SixPeaks acquisition show industry momentum.</li><li>Muscle-preservation aims to complement GLP-1s, not replace them. Improves long-term weight-loss quality.</li><li>PatentVest is MDBH&#039;s IP platform unit; could bolster MDBH&#039;s IP services exposure.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>MDB Capital Holdings (MDBH)</strong>: Parent company; PatentVest is its IP-focused unit; potential revenue upside from IP services growth.</li><li><strong>PatentVest (N/A)</strong>: MDBH subsidiary; IP intelligence platform; benefits from industry demand for IP insights.</li><li><strong>Eli Lilly (LLY)</strong>: Major obesity-therapy acquirer; signals demand for IP assets and collaboration opportunities.</li><li><strong>AstraZeneca (AZN)</strong>: Active in obesity IP space via SixPeaks; supports industry momentum for IP-centric strategies.</li><li><strong>Versanis Bio (N/A)</strong>: Acquired by Lilly; private company; context for sector consolidation.</li><li><strong>SixPeaks Bio (N/A)</strong>: Acquired by AstraZeneca; private company; indicates strategic interest in muscle-preservation programs.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>Industry News highlighting the shift toward IP-led obesity therapeutics and muscle-preservation strategies; underscores MDBH&#039;s positioning via PatentVest.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Growing obesity-therapy IP activity may expand demand for MDBH&#039;s IP services.</li><li>Lilly and AstraZeneca M&amp;A activity underscores sector confidence in muscle-preservation.</li><li>MDBH&#039;s ownership of PatentVest could monetize IP insights with pharma clients.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>June 4, 2026: PatentVest Pulse report release.</li><li>20 muscle-preservation programs identified.</li><li>Lilly acquired Versanis Bio and bimagrumab.</li><li>AstraZeneca acquired SixPeaks Bio.</li><li>PatentVest is a division of MDB Capital Holdings (NASDAQ: MDBH).</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>MDBH could gain modest upside via PatentVest over the next 6-12 months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="center">• Analysis of 20 muscle-preservation programs highlights a rapidly emerging category designed to enhance long-term obesity treatment outcomes</p>  <p align="center">• PatentVest's report reveals how combination therapy IP, body-composition optimization, and strategic acquisitions may shape the next phase of obesity therapeutics</p>  <p align="left">Dallas, Texas, June  04, 2026  (GLOBE NEWSWIRE) -- Today, PatentVest, a leading provider of IP Strategy and IP Law services, announces the release of its latest report, "<a href="https://www.globenewswire.com/Tracker?data=BNRoQD1VTrhO0NQNdcTckFFnwP-2aqIXP1AHndllxJYLuMKZ7GgXnzjdwtdpskmwebWNOqpd0Yc0a9tzJHAqJo3v67CtIk_6FW-5ygRBQiXYpL95vYxgvDYj-OHkI9om1b-2St-qv8ZYMicZ6aGe6zfPg_7dQAfe9IlkoQMmV5_mvnciYajn4CQrvqMuIQxBxvUCoNpijvodI5m6lCtZf0gPgOiAkNGBYAT5Q9jMwxCrvjsDvjsvJUHo_D37tm6adEOpfSo1KSvhLZ3OdEr8Fw==" rel="nofollow" target="_blank"><b><i><u>The Muscle Problem: </u></i></b><b><i><u>How Myostatin Could Expand the GLP-1 Opportunity</u></i></b></a>" This comprehensive study provides a strategic analysis of the emerging muscle-preservation category developing alongside obesity therapies.</p>  <p>The release comes as pharmaceutical companies and investors increasingly focus on therapies designed to improve body composition during GLP-1 treatment. While first-generation obesity therapies transformed weight-loss outcomes, growing attention is now being paid to preserving lean mass and improving the quality of weight loss during long-term treatment.</p>  <p>PatentVest's analysis suggests that muscle-preservation therapies may represent one of the most important emerging opportunities within the obesity ecosystem, creating new partnering, licensing, acquisition, and intellectual property opportunities across the sector.</p>  <p>The report highlights the structural shift underway in obesity therapeutics, driven by myostatin inhibition, ActRII blockade, and combination strategies designed to complement existing GLP-1 therapies. Key findings include:</p>  <p>• Emerging Category Growth: Identification of 20 muscle-preservation programs currently in development, signaling growing industry investment in therapies designed to enhance obesity treatment outcomes.</p>  <p>• Strategic Transactions: Analysis of major industry moves, including Eli Lilly's acquisition of Versanis Bio and bimagrumab and AstraZeneca's acquisition of SixPeaks Bio, highlighting increasing confidence in the category.</p>  <p>• Combination Therapy Opportunity: Findings suggest that muscle-preservation therapies are not intended to replace GLP-1s but rather to expand their long-term value through improved body composition and patient outcomes.</p>  <p>• Intellectual Property Positioning: Patent analysis reveals that GLP-1 combination of therapy patents, method-of-use claims, and pathway-specific intellectual property may become increasingly valuable as the category matures.</p>  <p>"The first phase of the obesity revolution was proving that meaningful pharmacological weight loss was possible," said Tyler Teske, Business Development &amp; Training Manager at PatentVest. "The next phase may focus on improving the quality of that weight loss. As new data continues to emerge, muscle-preservation therapies have the potential to become an important layer within the obesity ecosystem, creating new strategic opportunities for pharmaceutical companies, investors, and IP owners."</p>  <p>The PatentVest Pulse report is now available for download on the PatentVest website: <a href="https://insights.patentvest.com/the-muscle-problem-how-myostatin-could-expand-the-glp-1-opportunity" title="https://insights.patentvest.com/the-muscle-problem-how-myostatin-could-expand-the-glp-1-opportunity">https://insights.patentvest.com/the-muscle-problem-how-myostatin-could-expand-the-glp-1-opportunity</a></p>  <p>For more information or inquiries, please contact <a href="https://www.globenewswire.com/Tracker?data=S1FVcwV7PmcBj4ZLhNSuvWNfhJqcrawuGelakDCrDlzRNU-7MfDDqwBGKfH5712J6z6tiqnD5LRzflAMu-ObP_I0F9G0KWL5dsuAddmbHCk=" rel="nofollow" target="_blank">info@patentvest.com</a>.</p>  <p>The insights and analysis presented in this report are derived from PatentVest's proprietary IP intelligence platform, which integrates patent data, clinical pipeline analysis, transaction activity, and strategic market mapping to identify emerging trends and competitive positioning across biotechnology sectors.</p>  <p><strong>About PatentVest</strong></p>  <p align="left">PatentVest is the first integrated IP intelligence, strategy, and law firm built for companies where patents drive enterprise value. The firm pairs seasoned IP counsel with a dedicated analyst team and a proprietary technology platform to deliver portfolio strategy, diligence, and prosecution work with the rigor of Big Law and the speed modern innovators require. PatentVest Pulse, the firm&#39;s research series, maps the competitive and IP landscapes of frontier technology sectors, from brain-computer interfaces and humanoid robotics to AI infrastructure and next-generation therapeutics, giving investors, boards, and operators a clear view of who owns the innovation that will define each market. PatentVest is a division of MDB Capital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MDBH">MDBH</a>). Learn more at patentvest.com.</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTczMjA2NSM3NjM3MjY0IzUwMDEyNDY2Ng=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/M2IyY2M0NmUtN2JjYy00ZjJiLTkzNzItY2M5YWNlODZhMTg0LTUwMDEyNDY2Ni0yMDI2LTA2LTA0LWVu/tiny/PatentVest-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/600a6635-8e2f-41d9-b113-6139fe43166a"><img src="https://ml.globenewswire.com/media/600a6635-8e2f-41d9-b113-6139fe43166a/small/patentvest-logo97-copy-png.png" border="0" width="150" height="23" alt="Primary Logo"></img></a></p>

PatentVest released the Pulse report identifying 20 muscle-preservation programs and outlining how myostatin inhibition and GLP-1 combos could reshape obesity therapeutics. The findings highlight IP opportunities and strategic M&A activity (Lilly's Versanis Bio/bimagrumab and AstraZeneca's SixPeaks) that could expand demand for PatentVest's IP intelligence services, benefiting MDBH.

New PatentVest Pulse Report Maps the Emerging Muscle-Preservation Category Expanding the GLP-1 Opportunity

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Industry News

Related News